NIH SBIR After Reauthorization: What Changed for Phase I Applicants

Most of the conversation around SBIR reauthorization has focused on SBA and DoD. But NIH quietly distributes roughly $1.2 billion in SBIR and STTR awards every year across 24 institutes and centers, making it the second-largest funder in the program. And unlike agencies that furloughed program staff during the five-month lapse, NIH kept its Center for Scientific Review study sections intact. That decision means NIH is positioned to restart Phase I review faster than almost any other participating agency.

For biomedical and health technology companies waiting to submit, the question is no longer whether SBIR comes back. It is what the reauthorized program looks like — and how NIH's implementation will differ from what applicants knew before.

NIH's Review Machine Never Stopped

The Center for Scientific Review (CSR) manages more than 1,700 study sections that evaluate grant applications across every biomedical discipline. During the lapse, CSR continued operating because its review infrastructure supports the broader NIH portfolio — R01s, R21s, K awards — not just SBIR. Study section rosters were maintained and Scientific Review Officers stayed in place.

The bottleneck for restarting SBIR at NIH was never review capacity. It was legal authority. Once the new Omnibus Solicitation is issued, NIH can slot SBIR applications into existing study sections within weeks. Agencies that disbanded review panels face a much longer ramp-up.

Expected timeline: NIH will likely begin accepting Phase I applications in March-April 2026, with first reviews in summer 2026. Watch for the updated SBIR/STTR Omnibus Solicitation on the NIH SEED website.

What the New Rules Mean for Phase I

Several reauthorization provisions directly affect NIH Phase I awards:

Proposal caps. Agencies now have authority to limit how many active SBIR awards a single company can hold simultaneously. NIH has not announced its specific cap, but given the agency's recent six-application-per-year limit for research grant PIs, expect a similar constraint. Companies with large SBIR portfolios should plan accordingly.

Foreign risk screening. Enhanced foreign ownership and influence screening requirements intersect with NIH's existing disclosure rules around foreign components and Other Support documentation. Expect additional certification requirements at submission — particularly for projects involving international subcontractors or key personnel with foreign affiliations.

Strategic Breakthrough pathway. A new expedited pathway for proposals addressing national priorities. NIH institutes could use this to fast-track Phase I awards in pandemic preparedness, antimicrobial resistance, or AI-driven diagnostics. Details are pending.

Award amounts. The standard NIH SBIR Phase I award remains approximately $275,000 for a six-month to one-year performance period. Some institutes — notably NCI and NIAID — routinely fund above this baseline for complex therapeutic or device projects.

How NIH Scores Proposals Differently

If you have submitted SBIR proposals to DoD or NSF, NIH's review process will feel fundamentally different. NIH uses five criteria, each scored on a 1-9 scale (1 being exceptional):

• Significance: Does the project address an important health problem?
• Investigator(s): Are the PI and team qualified to execute?
• Innovation: Does the approach employ novel concepts or methods?
• Approach: Is the research strategy well-designed and feasible?
• Environment: Does the scientific environment contribute to success?

These feed into an overall Impact Score that reviewers assign holistically — not a simple average. Study sections convert Impact Scores into percentile rankings, and each institute sets its own payline. Paylines vary dramatically: NCI might fund to the 15th percentile while NIBIB funds to the 25th.

Commercialization now carries more weight. Under the reauthorized program, reviewers give greater scrutiny to commercial potential. This is a meaningful shift for an agency that historically prioritized scientific merit above market viability. Your Phase I proposal needs a credible path from bench to bedside, not just compelling science.

Open Topics, Directed Topics, and FOAs

NIH SBIR differs from DoD in one critical structural way: most funding flows through open topics rather than directed ones.

Open topics (Omnibus Solicitation): The majority of Phase I applications are submitted under a single, broad FOA that accepts investigator-initiated proposals across all 24 institutes. You choose which institute to target, and CSR routes your application to the appropriate study section.

Directed topics (contract solicitations): Some institutes — particularly NCI, NCATS, and NHLBI — issue specific solicitations for defined technology needs. These look more like DoD topics: the agency states a problem, you propose a solution. Posted individually on NIH SEED and SAM.gov.

Targeted FOAs: Individual institutes periodically release FOAs encouraging SBIR applications in specific areas. These signal where an institute is especially eager to fund — NIAID's FOAs on rapid diagnostics and NCI's notices on early detection are recent examples.

When the Omnibus reopens, search NIH SEED by institute to identify which ICs have active set-aside budgets. Targeting an institute with available funds dramatically improves your odds.

Preparing Your Phase I Application Now

You do not need to wait for the Omnibus to start preparing:

Update your eRA Commons profile. Every PI needs an active account. NIH will not review applications from PIs with incomplete profiles.

Verify your NAICS codes. Confirm your primary NAICS code in SAM.gov and ensure your SBA Company Registry profile is current. Registration delays have historically caused companies to miss submission windows.

Prepare NIH-format biosketches. NIH requires its own biosketch format — not NSF's, not a generic CV. Use SciENcv to generate compliant biosketches for all senior/key personnel.

Build your commercialization narrative. Given the increased weight on commercial potential, assemble your market analysis, IP position, regulatory pathway, and partnership strategy before you start writing. Reviewers expect this material to be substantive, not an afterthought.

Study your target institute's portfolio. NIH RePORTER lets you search funded SBIR awards by institute, keyword, and fiscal year. It reveals both the scientific areas in favor and the team compositions that succeed.

For deeper coverage of all SBIR agencies, see the reauthorization guide. For a walkthrough of the Phase I application itself, the SBIR Phase I guide covers everything from Omnibus structure to budget justification. And for teams aligning proposals with NIH health priorities, this breakdown of institute-level targeting remains directly relevant under the new rules.

The gap between reauthorization and the first new solicitation is the best preparation window applicants will get — tools like Granted can help you identify the right institute, match your technology to active funding areas, and build a submission-ready proposal before the deadlines arrive.